Guardant Health, Inc.

Guardant Health is a precision oncology company that develops blood- and tissue-based tests, real-world data platforms, and artificial intelligence analytics across the cancer care continuum. The company's diagnostic offerings span early screening, minimal residual disease detection, recurrence monitoring, and therapy selection for advanced-stage cancer. Core products include the Shield blood test for colorectal cancer screening, Guardant Reveal for recurrence monitoring, and the Guardant360 portfolio of liquid and tissue biopsy assays for genomic profiling. In addition, it provides research platforms such as GuardantINFINITY, GuardantOMNI, GuardantINFORM, and GuardantConnect. Customers comprise community and academic oncologists, primary care clinicians, cancer centers, health systems, and biopharmaceutical companies.

The company markets its products in the United States through a dedicated clinical sales force serving medical practices, health networks, and government medical facilities. Internationally, commercial reach extends to Europe, Asia, the Middle East, and Africa via distributor agreements, hospital relationships, and partner testing facilities in Spain, the United Kingdom, Italy, and China, along with regulatory and reimbursement approvals in Japan. The provided text does not disclose the company's headquarters location.

Summary of the business section of Guardant Health's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 2,506 employees, 2,490 of which are full-time employees and approximately 2,278 of which are in the U.S., with the remainder in Asia, Europe and Canada.”